Jubilant Pharmova growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+14.4%+7.9%+6.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.3%+30.3%+16.0%
+1.8%+55.2%+133.5%
−52.5%+1,050.3%+212.1%
−52.5%+988.1%+227.2%
+21.7%+10.5%+3.5%
+13.7%+15.1%+0.5%
+14.4%+10.4%+47.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JUBLPHARMA₹943.90

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹14,914 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+6.7+7.9+14.4—
EBITDA Growth—+16.0+30.3+7.3—
EBIT Growth—+133.5+55.2+1.8—
Net Income Growth—+212.1+1,050.3-52.5—
EPS Growth—+227.2+988.1-52.5—
Total Assets Growth—+3.5+10.5+21.7—
Total Equity Growth—+0.5+15.1+13.7—
Cash from Operations Growth—+47.0+10.4+14.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.